Sign in

    Adam Efrem • TD Cowen

    Adam Efrem is a Vice President and Equity Research Analyst at TD Cowen, specializing in the healthcare and biotechnology sectors with a focus on companies such as Prothena Corporation, Denali Therapeutics, and ACADIA Pharmaceuticals. He has been noted for his actionable investment calls and coverage of emerging trends, with performance metrics available from platforms like TipRanks that reflect a solid track record of accuracy and investor returns. Efrem started his professional career in finance after earning his degree, and prior to joining TD Cowen, he held analyst roles at other firms including E Squared. He holds active registrations with FINRA, maintaining Series 7 and 63 securities licenses and is recognized for his analytical rigor and industry insights.

    Adam Efrem's questions to Talkspace Inc (TALK) leadership

    Adam Efrem's questions to Talkspace Inc (TALK) leadership • Q3 2024

    Question

    Adam Efrem asked for clarification on the full-year 2024 adjusted EBITDA guidance of $4 million to $8 million, questioning what factors would lead to results at the high versus low end of the range given strong year-to-date performance. He also asked about the trajectory of the B2C business and member conversion to the B2B segment.

    Answer

    CFO Ian Harris stated that while revenue is expected to land slightly below the guidance midpoint, adjusted EBITDA is projected to reach the high end of the range, driven by successful cost optimization initiatives. He noted that recent covered lives growth from Medicare and military is foundational for 2025. CEO Dr. Jon Cohen explained the B2C segment's decline is a natural consequence of more users gaining insurance coverage, but a dedicated consumer market will persist for those who prefer to pay out-of-pocket.

    Ask Fintool Equity Research AI